These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8024657)

  • 1. Application of pharmacokinetically guided dose escalation with respect to cell cycle phase specificity.
    Fuse E; Kobayashi S; Inaba M; Suzuki H; Sugiyama Y
    J Natl Cancer Inst; 1994 Jul; 86(13):989-96. PubMed ID: 8024657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and phase I studies with rhizoxin to apply a pharmacokinetically guided dose-escalation scheme.
    Graham MA; Bissett D; Setanoians A; Hamilton T; Kerr DJ; Henrar R; Kaye SB
    J Natl Cancer Inst; 1992 Apr; 84(7):494-500. PubMed ID: 1545439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the hypoxic cell cytotoxic agent tirapazamine and its major bioreductive metabolites in mice and humans: retrospective analysis of a pharmacokinetically guided dose-escalation strategy in a phase I trial.
    Graham MA; Senan S; Robin H; Eckhardt N; Lendrem D; Hincks J; Greenslade D; Rampling R; Kaye SB; von Roemeling R; Workman P
    Cancer Chemother Pharmacol; 1997; 40(1):1-10. PubMed ID: 9137522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology and clinical toxicity of 4'-iodo-4'-deoxydoxorubicin: an example of successful application of pharmacokinetics to dose escalation in phase I trials.
    Gianni L; Viganò L; Surbone A; Ballinari D; Casali P; Tarella C; Collins JM; Bonadonna G
    J Natl Cancer Inst; 1990 Mar; 82(6):469-77. PubMed ID: 2313718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacokinetically guided dose-escalation (PGDE) strategy].
    Saeki T
    Gan To Kagaku Ryoho; 2000 Jul; 27(7):1069-74. PubMed ID: 10925698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interspecies differences in the kinetic properties of deoxycytidine kinase elucidate the poor utility of a phase I pharmacologically directed dose-escalation concept for 2-chloro-2'-deoxyadenosine.
    Reichelová V; Juliusson G; Spasokoukotskaja T; Eriksson S; Liliemark J
    Cancer Chemother Pharmacol; 1995; 36(6):524-9. PubMed ID: 7554045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics and toxicity of the anthrapyrazole anti-cancer drug CI-941 in the mouse: a guide for rational dose escalation in patients.
    Graham MA; Newell DR; Foster BJ; Calvert AH
    Cancer Chemother Pharmacol; 1989; 23(1):8-14. PubMed ID: 2909292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs.
    Evans WE; Rodman JH; Relling MV; Crom WR; Rivera GK; Pratt CB; Crist WM
    Med Pediatr Oncol; 1991; 19(3):153-9. PubMed ID: 2023562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Phase I trials--clinical studies of antineoplastic agents].
    Takahashi H; Wakui A; Yokoyama M; Oikawa H; Yoshioka T; Matsuoka S
    Gan To Kagaku Ryoho; 1991 Jul; 18(9):1477-85. PubMed ID: 1854218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies.
    Graham MA; Workman P
    Ann Oncol; 1992 May; 3(5):339-47. PubMed ID: 1616887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical pharmacokinetics of the anthrapyrazole CI-941: factors compromising the implementation of a pharmacokinetically guided dose escalation scheme.
    Graham MA; Newell DR; Foster BJ; Gumbrell LA; Jenns KE; Calvert AH
    Cancer Res; 1992 Feb; 52(3):603-9. PubMed ID: 1732048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative approaches for Phase I studies of anticancer drugs: a role for therapeutic drug monitoring.
    Evans WE
    Ther Drug Monit; 1993 Dec; 15(6):492-7. PubMed ID: 8122283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetically guided administration of chemotherapeutic agents.
    van den Bongard HJ; Mathôt RA; Beijnen JH; Schellens JH
    Clin Pharmacokinet; 2000 Nov; 39(5):345-67. PubMed ID: 11108434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma pharmacokinetics and pharmacodynamics of a new prodrug N-l-leucyldoxorubicin and its metabolites in a phase I clinical trial.
    de Jong J; Geijssen GJ; Munniksma CN; Vermorken JB; van der Vijgh WJ
    J Clin Oncol; 1992 Dec; 10(12):1897-906. PubMed ID: 1453205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficiency of targeting of antitumor drugs: simulation analysis based on pharmacokinetic/pharmacodynamic considerations.
    Nakai D; Fuse E; Suzuki H; Inaba M; Sugiyama Y
    J Drug Target; 1996; 3(6):443-53. PubMed ID: 8863137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
    Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
    Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between sensitivity in vitro of patient chronic lymphocytic leukemia cells and clinical systemic exposure at the maximum tolerated dose for cell cycle phase-specific (type 2) anticancer drugs.
    Fridborg H; Nygren N; Larsson R
    Anticancer Drugs; 1996 Jan; 7(1):105-8. PubMed ID: 8742106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro-in vivo correlation in anticancer drug sensitivity test using AUC-based concentrations and collagen gel droplet-embedded culture.
    Inaba M; Tashiro T; Sato S; Ohnishi Y; Tanisaka K; Kobayashi H; Koezuka M
    Oncology; 1996; 53(3):250-7. PubMed ID: 8643230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.